Issledovanie III fazy: znachitel'noe uvelichenie prodolzhitel'nosti zhizni u patsientov s naibolee rasprostranennym tipom nemelkokletochnogo raka legkogo, poluchavshikh prodolzhennuyu podderzhivayushchuyu terapiyu na osnove preparata Alimta
- 作者: - -
- 期: 卷 14, 编号 2 (2012)
- 页面: 5-
- 栏目: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/29470
- ID: 29470
如何引用文章
全文:
详细
参考
- Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543-51.
- Ciuleanu T et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009; 374 (9699): 1432-40.
- Paz-Ares LG et al. PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC). J Clin Oncol 2011; 29: abstract CRA 7510.